Pharmacokinetics of fucoxanthinol in human plasma after the oral administration of kombu extract

British Journal of Nutrition

Volumn 107, Issue 11, 2012, Pages 1566-1569

  Hashimoto, Takashi ^a   Ozaki, Yoshiaki ^a   Mizuno, Masashi ^a   Yoshida, Masaru ^b   Nishitani, Yosuke ^a   Azuma, Takeshi ^b   Komoto, Akitoshi ^c   Maoka, Takashi ^d   Tanino, Yuka ^a   Kanazawa, Kazuki ^a  

^a KOBE UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Ogurayayamamoto Company   (Japan)

^d RESEARCH INSTITUTE FOR PRODUCTION DEVELOPMENT   (Japan)

Author keywords

Fucoxanthin; Fucoxanthinol; Human subjects; Kombu (Laminaria japonica); Plasma

Indexed keywords

AMAROUCIAXANTHIN A; ASTAXANTHIN; BETA CAROTENE; FUCOXANTHIN; FUCOXANTHINOL; KOMBU EXTRACT; UNCLASSIFIED DRUG; XANTHOPHYLL;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LIVER FUNCTION TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; NORMAL HUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; BETA CAROTENE; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIETARY SUPPLEMENTS; FEMALE; HALF-LIFE; HUMANS; LAMINARIA; MALE; MIDDLE AGED; SPECTROPHOTOMETRY; XANTHOPHYLLS; YOUNG ADULT;

LAMINARIA JAPONICA; MUS;

EID: 84861869019     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114511004879     Document Type: Article

References (21)

1. Haugan JA, Aakermann T & Liaaen-Jensen S (1992) Isolation of fucoxanthin and peridinin. Methods Enzymol 213, 231-245.
2. Okuizumi J, Takahashi T, Yamane T, et al. (1993) Inhibitory effects of fucoxanthin, a natural carotenoid, on N-ethyl-N (-nitro-N-nitrosoguanidine- induced mouse duodenal carcinogenesis. Cancer Lett 68, 159-168.
3. Das SK, Hashimoto T, Baba M, et al. (2006) Japanese kelp (kombu) extract suppressed the formation of aberrant crypt foci in azoxymethane challenged mouse colon. J Clin Biochem Nutr 38, 119-125.
4. Kotake-Nara E, Kushiro M, Zhang H, et al. (2001) Carotenoids affect proliferation of human prostate cancer cells. J Nutr 131, 3303-3306.
5. Hosokawa M, Kudo M, Maeda H, et al. (2004) Fucoxanthin induces apoptosis and enhances the antiproliferative effect of the PPARg ligand, troglitazone, on colon cancer cells. Biochim Biophys Acta 1675, 113-119.
6. Das SK, Hashimoto T, Shimizu K, et al. (2005) Fucoxanthin induces cell cycle arrest at G0/G1 phase in human colon carcinoma cells through up-regulation of p21WAF1/Cip1. Biochim Biophys Acta 1726, 328-335.
7. Azuma Y, Hashimoto T, Nomura H, et al. (2008) Fucoxanthin induced apoptosis in human hepatocarcinoma HepG2 cells. J Clin Biochem Nutr 43, 273-276.
8. Maeda H, Hosokawa M, Sashima T, et al. (2006) Fucoxanthin and its metabolite, fucoxanthinol, suppress adipocyte differentiation in 3T3-L1 cells. Int J Mol Med 18, 147-152.
9. Maeda H, Hosokawa M, Sashima T, et al. (2005) Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues. Biochem Biophys Res Commun 332, 392-397.
10. Sugawara T, Baskaran V, Tsuzuki W, et al. (2002) Brown algae fucoxanthin is hydrolyzed to fucoxanthinol during absorption by Caco-2 human intestinal cells and mice. J Nutr 132, 946-951.
11. Asai A, Sugawara T, Ono H, et al. (2004) Biotransformation of fucoxanthinol into amaroucixanthin A in mice and HepG2 cells: formation and cytotoxicity of fucoxanthin metabolites. Drug Metab Dispos 32, 205-211.
12. Hashimoto T, Ozaki Y, Taminato M, et al. (2009) The distribution and accumulation of fucoxanthin and its metabolites after oral-administration in mice. Br J Nutr 102, 242-248.
13. Ozaki Y, Katsumata S, Uehara M, et al. (2008) Accumulation of fucoxanthin and its metabolites in mice after ad libitum administration of kombu extract-containing diet for one month. J Clin Biochem Nutr 43, (Suppl. 1), 269-272.
14. Asai A, Yonekura L & Nagao A (2008) Low bioavailability of dietary epoxyxanthophylls in humans. Br J Nutr 100, 273-277.
15. Tabata K, Yamaoka K, Kaibara A, et al. (1999) Moment analysis program available on Microsoft Excel. Xenobio Metabol Dispos 14, 286-293.
16. Novotny JA, Kurilich AC, Britz SJ, et al. (2005) Plasma appearance of labeled b-carotene, lutein, and retinol in humans after consumption of isotopically labeled kale. J Lipid Res 46, 1896-1903.
17. Mercke Odeberg J, Lignell A., Pettersson A, et al. (2003) Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations. Eur J Pharm Sci 19, 299-304.
18. Mordenti J (1986) Man versus beast: pharmacokinetic scaling in mammals. J Pharma Sci 75, 1028-1040.
19. Kistler A, Liechti H, Pichard L, et al. (2002) Metabolism and CYP-inducer properties of astaxanthin in man and primary human hepatocytes. Arch Toxicol 75, 665-675.
20. Toyokawa H (1978) Nutritional status in Japan from the viewpoint of numerical ecology. Soc Sci Med 12, 517-524.
21. Abidov M, Ramazanov Z, Seifulla R, et al. (2010) The effects of Xanthigen in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. Diabetes Obes Metab 12, 72-81.